The platelet-to-lymphocyte ratio could represent pro-thrombotic inflammatory state in acute ischemic stroke patients because having a high-PLR values increased the poor prognosis, the rate of insufficient recanalization, and the size of infarcted area.
The study results revealed the neuroprotective effects of ischemic preconditioning, supported with the upregulated pro-survival miRNAs in MCA infarcts.
The aim of this study was to evaluate the relationship between 25-hydroxyvitamin D (25(OH)D) levels and carpal tunnel syndrome (CTS). 25(OH)D levels were checked in 108 consecutive patients with CTS symptoms and 52 healthy controls. All patients underwent nerve conduction studies and completed Boston Carpal Tunnel Questionnaire (BQ) symptom severity and functional status scales to quantify symptom severity, pain status and functional status. There were 57 patients with electrophysiological confirmed CTS (EP+ group) and 51 electrophysiological negative symptomatic patients (EP- group). 25(OH) D deficiency (25(OH)D < 20 ng/ml) was found in 96.1 % of EP- group, in 94.7 % of EP+ group and in 73.8 % of control group. 25(0H) D level was found significantly lower both in EP+ and EP- groups compared to control group (p = 0.006, p < 0.001, respectively). Although mean vitamin D level in EP- group was lower than EP+ group, statistically difference was not significant between EP+ and EP- groups (p = 0.182). BQ symptom severity and functional status scores and BQ pain sum score were not significantly different between EP+ and EP- groups. We found no correlation with 25(OH) D level for BQ symptom severity, functional status and pain sum scores. 25(OH) D deficiency is a common problem in patients with CTS symptoms. As evidenced by the present study, assessment of serum 25(OH)D is recommended in CTS patients even with electrophysiological negative results.
BackgroundRemote ischemic preconditioning (IPreC) could provide tissue-protective
effect at a remote site by anti-inflammatory, neuronal, and humoral
signaling pathways.ObjectivesThe aim of the study was to investigate the possible protective effects of
remote IPreC on myocardium after transient middle cerebral artery occlusion
(MCAo) in streptozotocin- induced diabetic (STZ) and non-diabetic rats.Methods48 male Spraque Dawley rats were divided into eight groups: Sham, STZ, IPreC,
MCAo, IPreC+MCAo, STZ+IPreC, STZ+MCAo and STZ+IPreC+MCAo groups. We induced
transient MCAo seven days after STZ-induced diabetes, and performed IPreC 72
hours before transient MCAo. Remote myocardial injury was investigated
histopathologically. Bax, Bcl2 and caspase-3 protein levels were measured by
Western blot analysis. Total antioxidant status (TAS), total oxidant status
(TOS) of myocardial tissue were measured by colorimetric assay. Oxidative
stress index(OSI) was calculated as TOS-to-TAS ratio. For all statistical
analysis, p values < 0.05 were considered significant.ResultsWe observed serious damage including necrosis, congestion and mononuclear
cell infiltration in myocardial tissue of the diabetic and ischemic groups.
In these groups TOS and OSI levels were significantly higher; TAS levels
were lower than those of IPreC related groups (p < 0.05). IPreC had
markedly improved histopathological alterations and increased TAS levels in
IPreC+MCAo and STZ+IPreC+MCAo compared to MCAo and STZ+MCAo groups (p <
0.05). In non-diabetic rats, MCAo activated apoptotic cell death via
increasing Bax/Bcl2 ratio and caspase-3 levels. IPreC reduced apoptotic cell
death by suppressing pro-apoptotic proteins. Diabetes markedly increased
apoptotic protein levels and the effect did not reversed by IPreC.ConclusionsWe could suggest that IPreC attenuates myocardial injury via ameliorating
histological findings, activating antioxidant mechanisms, and inducing
antiapoptotic activity in diabetic rats.
AIm: Current stroke therapies include lipid-lowering drugs, which reduce inflammation and serve to stabilize the atherosclerotic plaque to demonstrate better outcome and neuroprotection. Peroxisome proliferator activated receptors (PPAR) α regulates lipid homeostasis and is a target of fibrates, which have a neuroprotective function by various mechanisms. In this study, we aimed to evaluate the role of the PPARα agonist, fenofibrate, in the modulation of cleaved caspase-3 immunoreactivity and at the final infarct volume in an experimental ischemia/reperfusion rat model by induced transient proximal middle cerebral artery occlusion. mATERIAl and mEThODS: A total of 65 male Sprague Dawley rats were allocated into 4 groups; sham (n =5), experiment 1 (n=20), experiment 2 (n=20), experiment 3 (n=20). All experiment groups were divided to 3 subgroups in order to evaluate the final infarct volume at 24 th hour (n=5) and the immunoreactivity of cleaved caspase -3 at different time periods [at first hour (n=5), at 6 th hour (n=5), at 24 th hour (n=5)] after transient middle cerebral artery occlusion (MCAo). At the study, the experiment groups (Experiment 1 and Experiment 2) were received the fenofibrate-diet during 14 days before ischemia procedure. All animals were sacrificed at 24 th hours after MCAo. Infarction volumes were calculated from 2,3,5,triphenyltetrozolium chloride (TTC)-stained brain sections.
RESUlTS:We found that fenofibrate-therapy reduced significantly more body weight than the other experiment groups (p<0.05). At the time intervals, a decrease of immunoreactivity of cleaved caspase-3 was significantly observed with fenofibrate therapy after MCAo (p<0.05). Chronic fenofibrate treatment before cerebral ischemia significantly reduced the infarction size after MCAo compared with the other groups (respectively; p = 0.011 and p< 0.000).
CONClUSION:Fenofibrate treatment has neuroprotective effects on middle cerebral artery infarcts.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.